VBI Vaccines Company Profile (NASDAQ:VBIV)

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines logoVBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VBIV
  • CUSIP: N/A
  • Web: www.vbivaccines.com
Capitalization:
  • Market Cap: $159.44 million
  • Outstanding Shares: 40,229,000
Average Prices:
  • 50 Day Moving Avg: $3.77
  • 200 Day Moving Avg: $4.53
  • 52 Week Range: $2.75 - $6.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $888,999.00
  • Price / Sales: 180.10
  • Book Value: $1.72 per share
  • Price / Book: 2.31
Profitability:
  • EBIDTA: ($32,880,000.00)
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 2.00%
  • Quick Ratio: 1.91%
Misc:
  • Average Volume: 145,435 shs.
  • Beta: 2.57
  • Short Ratio: 10.25
 

Frequently Asked Questions for VBI Vaccines (NASDAQ:VBIV)

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Where is VBI Vaccines' stock going? Where will VBI Vaccines' stock price be in 2017?

2 brokerages have issued 1 year price objectives for VBI Vaccines' stock. Their predictions range from $6.00 to $6.00. On average, they expect VBI Vaccines' share price to reach $6.00 in the next twelve months. View Analyst Ratings for VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

Who owns VBI Vaccines stock?

VBI Vaccines' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Clarus Ventures LLC (6.72%), Cambridge Investment Research Advisors Inc. (3.43%), Northern Trust Corp (0.50%), State Street Corp (0.47%), Vanguard Group Inc. (0.32%) and Bank of Montreal Can (0.16%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter and Perceptive Advisors Llc. View Institutional Ownership Trends for VBI Vaccines.

Who sold VBI Vaccines stock? Who is selling VBI Vaccines stock?

VBI Vaccines' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for VBI Vaccines.

Who bought VBI Vaccines stock? Who is buying VBI Vaccines stock?

VBI Vaccines' stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp, State Street Corp, TIAA CREF Investment Management LLC, Teachers Advisors LLC, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., California State Teachers Retirement System and Bank of Montreal Can. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter and Perceptive Advisors Llc. View Insider Buying and Selling for VBI Vaccines.

How do I buy VBI Vaccines stock?

Shares of VBI Vaccines can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBI Vaccines stock can currently be purchased for approximately $3.98.


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VBI Vaccines (NASDAQ:VBIV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (50.75% upside)

Analysts' Ratings History for VBI Vaccines (NASDAQ:VBIV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/31/2017Noble FinancialReiterated RatingBuyHighView Rating Details
10/10/2016LaidlawInitiated CoverageBuy$6.00N/AView Rating Details
7/26/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for VBI Vaccines (NASDAQ:VBIV)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for VBI Vaccines (NASDAQ:VBIV)
Current Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for VBI Vaccines (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VBI Vaccines (NASDAQ:VBIV)
Insider Ownership Percentage: 54.50%
Institutional Ownership Percentage: 31.52%
Insider Trades by Quarter for VBI Vaccines (NASDAQ:VBIV)
Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)
Insider Trades by Quarter for VBI Vaccines (NASDAQ:VBIV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Francisco Diaz-MitomaInsiderBuy3,000$3.17$9,510.00View SEC Filing  
8/21/2017Jeff BaxterCEOBuy10,000$3.22$32,200.00View SEC Filing  
8/10/2017Jeff BaxterCEOBuy10,000$3.28$32,800.00View SEC Filing  
12/6/2016Perceptive Advisors LlcMajor ShareholderBuy3,383,955$3.05$10,321,062.75View SEC Filing  
8/14/2015Perceptive Advisors LlcMajor ShareholderBuy650,000$2.08$1,352,000.00View SEC Filing  
9/30/2013Murray George SmithCFOBuy3,027$1.13$3,420.51View SEC Filing  
8/21/2013Murray George SmithCFOBuy8,973$1.17$10,498.41View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for VBI Vaccines (NASDAQ:VBIV)
Latest Headlines for VBI Vaccines (NASDAQ:VBIV)
Source:
DateHeadline
americanbankingnews.com logoVBI Vaccines, Inc. (VBIV) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - September 19 at 10:12 AM
americanbankingnews.com logoZacks Investment Research Downgrades VBI Vaccines, Inc. (VBIV) to Sell
www.americanbankingnews.com - September 12 at 12:00 PM
finance.yahoo.com logoVBI Vaccines to Present at September 2017 Investor Conferences
finance.yahoo.com - September 12 at 11:46 AM
americanbankingnews.com logoReviewing VBI Vaccines (VBIV) & SIGA Technologies (SIGA)
www.americanbankingnews.com - September 5 at 10:22 AM
americanbankingnews.com logoVBI Vaccines, Inc. (VBIV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 5 at 9:06 AM
finance.yahoo.com logoVBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
finance.yahoo.com - August 30 at 10:42 AM
finance.yahoo.com logoVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
finance.yahoo.com - August 29 at 9:19 AM
finance.yahoo.com logoETFs with exposure to VBI Vaccines, Inc. : August 28, 2017
finance.yahoo.com - August 29 at 9:19 AM
finance.yahoo.com logoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:14 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - August 23 at 11:10 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) CEO Jeff Baxter Purchases 10,000 Shares
www.americanbankingnews.com - August 22 at 7:56 PM
finance.yahoo.com logoETFs with exposure to VBI Vaccines, Inc. : August 18, 2017
finance.yahoo.com - August 19 at 8:45 AM
finance.yahoo.com logoVBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
finance.yahoo.com - August 15 at 3:35 PM
americanbankingnews.com logoJeff Baxter Purchases 10,000 Shares of VBI Vaccines, Inc. (NASDAQ:VBIV) Stock
www.americanbankingnews.com - August 15 at 12:16 AM
finance.yahoo.com logoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q1, 2017 By the Numbers : August 7, 2017
finance.yahoo.com - August 8 at 8:02 AM
americanbankingnews.com logoVBI Vaccines, Inc. (NASDAQ:VBIV) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - August 3 at 11:40 PM
americanbankingnews.com logoZacks Investment Research Lowers VBI Vaccines, Inc. (VBIV) to Sell
www.americanbankingnews.com - August 1 at 11:08 AM
americanbankingnews.com logoVBI Vaccines, Inc. (VBIV) Receives Buy Rating from Noble Financial
www.americanbankingnews.com - July 31 at 9:40 AM
finance.yahoo.com logoVBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
finance.yahoo.com - July 27 at 9:01 AM
americanbankingnews.com logoVBI Vaccines, Inc. (VBIV) Short Interest Up 163.4% in June
www.americanbankingnews.com - July 16 at 7:14 AM
americanbankingnews.com logoZacks Investment Research Lowers VBI Vaccines, Inc. (VBIV) to Hold
www.americanbankingnews.com - July 15 at 10:16 AM
seekingalpha.com logoVBI Vaccines' (VBIV) CEO Jeff Baxter on Phase 3 Clinical Program for Sci-B-Vac Hepatitis B Vaccine Conference Call (Transcript)
seekingalpha.com - July 14 at 9:41 AM
finance.yahoo.com logoVBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine
finance.yahoo.com - July 12 at 8:53 AM
americanbankingnews.com logoVBI Vaccines, Inc. (NASDAQ:VBIV) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 12 at 8:50 AM
finance.yahoo.com logoVBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
finance.yahoo.com - June 26 at 3:24 PM
streetinsider.com logoVBI Vaccines (VBIV) Announces Positive Outcome from Phase III Pre-IND Discussions with FDA for Hepatitis B Vaccine, Sci-B-Vac
www.streetinsider.com - June 21 at 6:25 AM
finance.yahoo.com logoVBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)
finance.yahoo.com - June 19 at 8:35 AM
americanbankingnews.com logoVBI Vaccines, Inc. (VBIV) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 14 at 2:20 PM
finance.yahoo.com logoVBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 11:22 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Downgraded by TheStreet to "D+"
www.americanbankingnews.com - June 5 at 12:28 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - June 3 at 12:12 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - June 2 at 11:58 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Receives Buy Rating from Noble Financial
www.americanbankingnews.com - May 28 at 8:56 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Given Buy Rating at Noble Financial
www.americanbankingnews.com - May 6 at 5:44 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:08 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Getting Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 3:52 PM
finance.yahoo.com logoVBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
finance.yahoo.com - May 2 at 6:34 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Earning Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 29 at 11:35 AM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Earns Daily News Sentiment Rating of 0.04
www.americanbankingnews.com - April 26 at 10:20 AM
finance.yahoo.com logo3 Different Companies, 3 Different Approaches to Tumors
finance.yahoo.com - April 24 at 6:51 PM
americanbankingnews.com logoVBI Vaccines, Inc. - (VBIV) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 19 at 9:39 AM
finance.yahoo.com logoVBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress
finance.yahoo.com - April 7 at 1:18 PM
finance.yahoo.com logoVBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site
finance.yahoo.com - March 31 at 6:26 AM
americanbankingnews.com logoZacks: Brokerages Set $8.50 Price Target for VBI Vaccines, Inc. - (VBIV)
www.americanbankingnews.com - March 29 at 11:44 AM
feeds.benzinga.com logoMeet VBI Vaccines, The Biotech Up 100% In 2017
feeds.benzinga.com - March 7 at 1:36 PM
streetinsider.com logoVBI Vaccines (VBIV) Announces Positive Response from Health Canada's Initial Evaluation of Sci-B-Vac Phase III Clinical Program
www.streetinsider.com - February 23 at 3:06 AM
finanznachrichten.de logoVBI VACCINES INC
www.finanznachrichten.de - February 23 at 3:06 AM
us.rd.yahoo.com logoVBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program
us.rd.yahoo.com - February 22 at 10:46 AM
us.rd.yahoo.com logoVBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study
us.rd.yahoo.com - February 7 at 3:49 PM
finance.yahoo.com logoVBIV: Notable Investors and Multiple Upcoming Catalysts Make VBIV a Stock to Watch in 2017
finance.yahoo.com - February 3 at 6:35 AM

Social

Chart

VBI Vaccines (VBIV) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff